Drug Transcytosis
Drug Transcytosis - Related Videos
02:28
Assessing Transcytosis of E. coli Across Intestinal Epithelial Monolayers
0 Views •
2025
Source: Islam, A., et al., Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates. J. Vis. Exp. (2023)This video demonstrates the procedure for assessing transcytosis of neonatal Escherichia coli across intestinal epithelial monolayers using transwell inserts, electrical resistance measurement, and bacterial quantification.
01:15
Transcytosis of IgG
0 Views •
2023
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis. IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
00:58
Recycling Endosomes and Transcytosis
0 Views •
2023
The recycling endosome, also known as the endosomal recycling compartment (ERC), is a part of the slow-recycling process of the endocytic pathway. Molecules internalized through receptor-mediated endocytosis are either degraded in the lysosomes or are recycled to the plasma membrane through the fast- or slow-recycling route. The recycling endosome is not a single organelle but an extensively tubulated network of recycling pathways. It functions in storing molecules or transporting them across...
01:18
Vesicular Trasport: Endocytosis, Transcytosis and Exocytosis
0 Views •
2024
Vesicular transport is a cellular process that encompasses the engulfment of particles or dissolved substances by cells. It involves endocytosis, transcytosis, and exocytosis. Endocytosis is a cellular mechanism that involves the inward folding of the cell membrane to create vesicles that capture and transport large drug molecules. This process comprises two distinct methods: pinocytosis (often referred to as "cell drinking") and phagocytosis (often referred to as "cell eating"). Pinocytosis is...
08:32
Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
0 Views •
Cited by 1 •
2023
Escherichia coli causes sepsis in neonates who ingest the bacteria around the time of birth. The process involved in E. coli’s ability to travel from the enteric tract to the bloodstream is poorly understood. This in vitro model assesses the ability of E. coli strains to travel through the intestinal epithelial cells.
FAQs
After binding a surface receptor, the therapeutic molecule or carrier enters the cell through endocytosis and is enclosed in an endosome. The endosome provides an intracellular transport compartment, allowing the cargo to move through the cell before release by exocytosis at the opposite surface. This route supports passage across a polarized cell layer rather than simple exposure to one side.
Avoiding lysosomal degradation helps preserve the therapeutic cargo during its passage through the cell. In receptor-mediated transcytosis, the molecule or carrier remains associated with an endosomal pathway that leads toward exocytosis on the opposite side. This distinction matters because degradation would reduce the amount of intact therapeutic material available beyond the cellular barrier.
Cell polarity gives the layer two functionally distinct sides and makes the direction of transport important. A molecule must enter from one surface, move through the endosomal compartment, and exit from the opposite surface to cross the layer effectively. This organization is especially relevant when a therapy must reach protected or poorly accessible tissues beyond an endothelial barrier.
Evaluation follows the pathway from receptor engagement and endocytic entry to endosomal movement and exocytotic release on the opposite side of the cell layer. Researchers can then consider whether the process enables the therapeutic molecule or carrier to cross the barrier and reach the intended tissue. In cancer studies, this sequence helps connect cellular transport with tumor delivery.
The source material identifies antibodies, nanoparticles, and other targeted therapeutics as relevant cargo formats. Their transport through tumor-associated endothelial cells can support delivery across biological barriers and into tumors. This broadens the application beyond a single drug type, while retaining the importance of receptor binding, intracellular trafficking, and release on the tissue-facing side.
Improving transcytosis may increase therapeutic accumulation at tumor sites while limiting exposure to healthy tissues. In cancer research, this creates a delivery objective: move more antibody, nanoparticle, or other targeted therapeutic across tumor-associated endothelial cells and toward the tumor, without relying solely on unrestricted distribution throughout the body. The intended outcome is more localized drug access.